Results and presentations
Home / Investor relations / Results and presentations
Latest results announcements and presentations
2024
Full Year and Q4 2023 results
8 February 2024
J.P. Morgan 42nd Annual Healthcare Conference
9 January 2024
2023
9M and Q3 2023 results
9 November 2023
Meet AZN management: European Society of Medical Oncology 2023 Annual Meeting
23 October 2023
Morgan Stanley 21st Annual Global Healthcare Conference
11 September 2023
2023 World Conference on Lung Cancer (WCLC) highlights
11 September 2023
H1 and Q2 2023 results
28 July 2023
Meet AZN management: American Society of Clinical Oncology 2023 Annual Meeting
5 June 2023
Q1 2023 results
27 April 2023
2023 American Association for Cancer Research (AACR) highlights
19 April 2023
2022 Sustainability Highlights
22 March 2023
Full Year and Q4 2022 results
9 February 2023
J.P. Morgan 41st Annual Healthcare Conference
9 January 2023
2022
Meet AZN management: San Antonio Breast Cancer Symposium (SABCS) 2022
8 December 2022
Year-to-date and Q3 2022 results
10 November 2022
Meet AZN Management: Alexion Rare Disease Deep Dive
6 September 2022
H1 2022 results
29 July 2022
Meet AZN management: American Society of Clinical Oncology 2022 Annual Meeting
6 June 2022
Q1 2022 results
29 April 2022
March 2022 Roadshow presentation
16 March 2022
Meet AZN management: Leading in sustainability
7 March 2022
Investor science conference call: ASCO GU 2022
23 February 2022
Full-year and Q4 2021 results
10 February 2022
Investor science conference call: ASCO GI 2022
24 January 2022
2021
Year-to-date and Q3 2021 results
12 November 2021
Investor science conference call: ESMO 2021
20 September 2021
H1 2021 results
29 July 2021
Meet AZN management: Oncology - 2021 ASCO Annual Meeting
7 June 2021
Q1 2021 results
30 April 2021
Meet AZN management: BioPharmaceuticals
25 March 2021
Full-year 2020 results
11 February 2021
2020
Accelerating AstraZeneca’s strategic and financial development:
AstraZeneca to acquire Alexion
12 December 2020
Year-to-date and Q3 2020 results
5 November 2020
Meet AZN management: Leading in sustainability
9 September 2020
Investor science conference call: Farxiga’s DAPA-CKD trial at ESC 2020
30 August 2020
H1 2020 results
30 July 2020
Capital markets event - Meet AZN management: ASCO 2020
1 June 2020
First-quarter 2020 results
29 April 2020
Full-year and Q4 2019 results
14 February 2020
Epidemiology data update
14 February 2020
2019
Investor science conference call: American Society of Hematology 2019
10 December 2019
Investor science conference call: American College of Rheumatology 2019
13 November 2019
Investor science conference call: American Society of Nephrology Kidney Week 2019
11 November 2019
Year-to-date and Q3 2019 Results
24 October 2019
Investor science conference call: European Society for Medical Oncology (ESMO) Congress 2019
30 September 2019
Investor science conference call: Farxiga's DAPA-HF trial at ESC 2019
1 September 2019
H1 2019 Results
25 July 2019
‘Meet AZN management’ at 2019 ASCO Annual Meeting
3 June 2019
Q1 2019 Results
26 April 2019
Collaboration on trastuzumab deruxtecan Investor conference call
29 March 2019
Full-Year 2018 Results
14 February 2019
2018
Year-end webcast for investors and analysts on China and Emerging Markets
13 December 2018
AHA Scientific Sessions 2018
12 November 2018
Year-To-Date and Q3 2018 Results
8 November 2018
H1 2018 Results
26 July 2018
AstraZeneca Investor Event at the 2018 ASCO Annual Meeting
1 June 2018
Q1 2018 Results
18 May 2018
Full-Year 2017 Results
2 February 2018
2017
Investor science event: Late-stage pipeline webcast
14 December 2017
Year-To-Date and Q3 2017 Results
9 November 2017
AstraZeneca Investor Science Event at ERS 2017
13 September 2017
AstraZeneca Investor Science Event at ESMO 2017
8 September 2017
H1 2017 Results
27 July 2017
AstraZeneca Investor Science Event at 2017 ASCO Annual Meeting
5 June 2017
Q1 2017 Results
27 April 2017
Full-Year and Q4 2016 Results
2 February 2017
Upcoming events
SEC filings
SEC filings are those documents that we are required to file by virtue of our listing on Nasdaq. They contain mainly financial information.
These documents are also available for viewing on the SEC website at www.sec.gov. The Company will send any holder of the Company’s securities, upon request, a hard copy of the Company’s complete audited financial statements free of charge. Requests may be made by writing to:
Company Secretary
AstraZeneca PLC
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
Annual Reports
Archive
Investor enquiries
Main Contacts
Andy Barnett
Head of Investor Relations
Isabel Gibson
Oncology
Christer Gruvris
BioPharmaceuticals
(Cardiovascular, Renal and Metabolism),
Finance & Fixed Income
Rachel Korolyshun
Rare Disease,
Environment, Social and Governance
Morgan Sanford
Oncology
Philip Sparks
BioPharmaceuticals
(Respiratory & Immunology, Vaccines & Immune Therapies)
Lauren Swales
Rare Disease,
Environment, Social and Governance